Anna Kloska

List of Publications by Year
in descending order

30 papers	759 citations	430754 18 h-index	526166 27 g-index
32 all docs	32 docs citations	32 times ranked	906 citing authors

#	Article	IF	Citations
1	Cellular and Gene Expression Response to the Combination of Genistein and Kaempferol in the Treatment of Mucopolysaccharidosis Type I. International Journal of Molecular Sciences, 2022, 23, 1058.	1.8	5
2	Three Microbial Musketeers of the Seas: Shewanella baltica, Aliivibrio fischeri and Vibrio harveyi, and Their Adaptation to Different Salinity Probed by a Proteomic Approach. International Journal of Molecular Sciences, 2022, 23, 619.	1.8	2
3	Global Changes of 5-mC/5h-mC Ratio and Methylation of Adiponectin and Leptin Gene in Placenta Depending on Mode of Delivery. International Journal of Molecular Sciences, 2021, 22, 3195.	1.8	4
4	Dosage Compensation in Females with X-Linked Metabolic Disorders. International Journal of Molecular Sciences, 2021, 22, 4514.	1.8	8
5	Virusâ€“Host Interaction Gets Curiouser and Curiouser. PART I: Phage P1vir Enhanced Development in an E. coli DksA-Deficient Cell. International Journal of Molecular Sciences, 2021, 22, 5890.	1.8	2
6	Virusâ€“Host Interaction Gets Curiouser and Curiouser. PART II: Functional Transcriptomics of the E. coli DksA-Deficient Cell upon Phage P1vir Infection. International Journal of Molecular Sciences, 2021, 22, 6159.	1.8	4
7	The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy. Diabetes Research and Clinical Practice, 2020, 166, 108337.	1.1	7
8	Lipophagy and Lipolysis Status in Lipid Storage and Lipid Metabolism Diseases. International Journal of Molecular Sciences, 2020, 21, 6113.	1.8	37
9	Adaptation of the Marine Bacterium Shewanella baltica to Low Temperature Stress. International Journal of Molecular Sciences, 2020, 21, 4338.	1.8	18
10	Lipids and Lipid Mediators Associated with the Risk and Pathology of Ischemic Stroke. International Journal of Molecular Sciences, 2020, 21, 3618.	1.8	40
11	The Role of Dimethyl Sulfoxide (DMSO) in Gene Expression Modulation and Glycosaminoglycan Metabolism in Lysosomal Storage Disorders on an Example of Mucopolysaccharidosis. International Journal of Molecular Sciences, 2019, 20, 304.	1.8	26
12	Antimicrobial, cytotoxic, and antioxidant activities and physicochemical characteristics of chromium(III) complexes with picolinate, dipicolinate, oxalate, 2,2â€²-bipyridine, and 4,4â€²-dimethoxy-2,2â€²-bipyridine as ligands in aqueous solutions. Journal of Molecular Liquids, 2019, 282, 441-447.	2.3	13
13	Antioxidant and Cytoprotective Activity of Oxydiacetate Complexes of Cobalt(II) and Nickel(II) with 1,10-Phenantroline and 2,2â€²-Bipyridine. Biological Trace Element Research, 2018, 185, 244-251.	1.9	11
14	Female Fabry disease patients and X-chromosome inactivation. Gene, 2018, 641, 259-264.	1.0	44
15	Glycosaminoglycans and mucopolysaccharidosis type III. Frontiers in Bioscience - Landmark, 2016, 21, 1393-1409.	3.0	32
16	Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids. Scientific Reports, 2015, 5, 9378.	1.6	44
17	Physicochemical and Biological Properties of Oxovanadium(IV), Cobalt(II) and Nickel(II) Complexes with Oxydiacetate Anions. Biological Trace Element Research, 2015, 164, 139-149.	1.9	19
18	Riboregulation of the bacterial actin-homolog MreB by DsrA small noncoding RNA. Integrative Biology (United Kingdom), 2015, 7, 128-141.	0.6	18

#	Article	IF	Citations
19	Combined Therapies for Lysosomal Storage Diseases. Current Molecular Medicine, 2015, 15, 746-771.	0.6	16
20	Synthetic genistein derivatives as modulators of glycosaminoglycan storage. Journal of Translational Medicine, 2012, 10, 153.	1.8	20
21	Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. American Journal of Medical Genetics, Part A, 2012, 158A, 450-454.	0.7	26
22	Female Hunter syndrome caused by a single mutation and familial XCI skewing: implications for other X-linked disorders. Clinical Genetics, 2011, 80, 459-465.	1.0	21
23	Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metabolic Brain Disease, 2011, 26, 1-8.	1.4	52
24	Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expressionâ€targeted isoflavone therapy (GET IT). American Journal of Medical Genetics, Part A, 2011, 155, 2257-2262.	0.7	46
25	Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochemical Society Transactions, 2010, 38, 695-701.	1.6	54
26	Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?. Medical Hypotheses, 2010, 75, 605-609.	0.8	48
27	Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. European Journal of Pediatrics, 2008, 167, 203-209.	1.3	23
28	Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. Current Therapeutic Research, 2008, 69, 166-179.	0.5	92
29	A bacterial model for studying effects of human mutations in vivo: Escherichia coli strains mimicking a common polymorphism in the human MTHFR gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 578, 175-186.	0.4	8
30	Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human Î±-L-iduronidase (laronidase, Aldurazyme). American Journal of Medical Genetics, Part A, 2005, 139A, 199-203.	0.7	19